Vera Therapeutics, Inc. (VERA): Cash & Equivalents
$354.73M
As of 2025-12-31
$48.88M
As of 2026-06-30
+101.3%
3-year compound annual growth
+45.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $354.73M | +282.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $92.65M | +102.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $45.68M | +5.1% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $43.46M | -45.5% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $79.67M | +48.5% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $53.65M | n/a | 2022-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $354.73M | +282.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $225.27M | +114.8% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $80.16M | -3.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $142.90M | +42.2% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $628.11M | -28.6% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $165.81M | +521.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
Compare VERA, KURA, SDGR, SMMT side by side · Screen every company in Pharmaceutical Preparations ↗